dr. scott tagawa discusses immu-132 in patients with urothelial carcinoma
Published 8 years ago • 386 plays • Length 1:31
Download video MP4
Download video MP3
Similar videos
-
1:40
dr. tagawa on immu-132 trial updates in urothelial cancer
-
1:51
dr. tagawa on remaining questions with psma-targeted radionuclide therapy in mcrpc
-
1:38
dr. tagawa on sacituzumab govitecan in urothelial carcinoma
-
2:04
dr. tagawa discusses the development of immunotherapy in urothelial cancer
-
1:18
dr. tagawa on next steps with sacituzumab govitecan in advanced urothelial carcinoma
-
2:29
dr. tagawa on brca2 in patients with prostate cancer receiving psma-targeted radionuclide therapy
-
4:13
scott tagawa, md, on the prostate cancer treatment pipeline
-
7:17
scott tagawa, md, on psma targeting in prostate cancer treatment
-
1:49
dr. tagawa on preliminary data with 225ac-j591 in mcrpc
-
2:06
dr. tagawa on ctc in neuroendocrine-positive prostate cancer
-
1:18
dr. tagawa discusses radiotherapy in prostate cancer
-
1:09
dr. guarino on immu-132 in advanced metastatic lung cancer
-
9:23
scott tagawa, m.d. on psma pet-ct and its utility in prostate cancer - part 1
-
3:55
bladder cancer - 9th most common type of cancer in the world.
-
3:25
scott tagawa, md, discusses the results of phase i dose-escalation study regarding mcrpc
-
44:20
systemic therapies for advanced urothelial cancer
-
1:21
scott tagawa, md, on promising psma products in development for prostate cancer treatment
-
2:21
bladder cancer with urologist dr. scott davidson
-
5:49
scott tagawa, md, on the impact of racial disparity and covid-19 on prostate cancer clinical trials
Clip.africa.com - Privacy-policy